Exploring the synergy of combining immunotherapy 온라인 바카라102 with Lanova’s Claudin18.2 ADC
[by Ji, Yong Jun] GI Innovation announced on January 20 that it signed a memorandum of understanding (MOU) with China-based LaNova Medicines to co-develop a combination therapy involving its novel drug candidate '온라인 바카라102' and a Claudin18.2-targeting antibody-drug conjugate (ADC) for pancreatic cancer. The agreement was formalized on January 15 during the JP Morgan Healthcare Conference in San Francisco. USA.
In 2023, 온라인 바카라 licensed its multiple myeloma candidate 'LM-305' to AstraZeneca in a deal worth KRW 800 billion (approximately USD 551.9 million), including a non-refundable upfront payment of KRW 73.5 billion. In November 2024, the company gained global attention by licensing its phase 1 bispecific antibody candidate 'LM-299' to MSD in a KRW 4.6 trillion deal, which included a KRW 830 billion upfront fee for the PD-1·VEGF dual-target therapy.
Both companies have been collaborating on research involving the combination therapy of the immunotherapy drug '온라인 바카라102' and the ADC 'LM-302' targeting Claudin18.2. Recently, they observed promising anticancer activity in a preclinical pancreatic cancer model.
The two novel drug candidates have completed phase 1 clinical trials and are poised to rapidly enter phase 2 clinical trials. LM-302 is currently in phase 3 trials in China. 온라인 바카라 Innovation noted that there are no approved immunotherapy treatments for pancreatic cancer, and the only available option is a chemotherapy cocktail, which has a limited effectiveness and high toxicity. Under this agreement, the companies plan to focus on clinical development targeting patients with terminal pancreatic cancer.
“온라인 바카라102 is a prime example of GI Innovation’s exceptional immunotherapy R&D capabilities,” said Dr. Crystal Quin, CEO of LaNova Medicines. “We are thrilled to explore the potential of combining Lanova’s Claudin18.2 ADC, LM-302, with 온라인 바카라102, and believe that this combination could offer a new treatment option for pancreatic cancer patients.”
“We are excited to be conducting a combination study with LaNova, which is recognized by global pharmaceutical companies,” expressed Jang Myoung-ho, Chief Strategy Officer (CSO) of GI Innovation. “LaNova’s ADC, which directly targets and destroys tumor cells to increase response rates, and 온라인 바카라102, which enhances immune cell memory to increase overall survival, are expected to form a combination therapy that could transform the pancreatic cancer treatment paradigm,” he added.